Trevena Inc (TRVN-Q) Stock Price and News - The Globe and Mail

Add to Watchlist Create Alerts

Real-Time Last Update

Last Sale Cboe BZX Real-Time

Volume

Day Low0.4200

Day High0.4398

Open:0.4300

Previous Close

52-Week High/Low

Volume

Average Volume

Price/Earnings (TTM)

Forward Annual Dividend & Yield

Market Capitalization, $M

5-Day Change

Realtime quote and/or trade prices are not sourced from all markets.

AllPennyStocks.com

Biotech Shares Are Running Again!

September 6, 2023

Global Alzheimer's Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

Spotlight Growth

Trevena (NASDAQ: TRVN) Partner Receives Approval for OLINVYK in China

Trevena Reports Second Quarter 2022 Results and Provides Business Update

August 11, 2022

Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock

Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update

Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative Care

Trevena to Participate at the JMP Securities Life Sciences Conference

Trevena to Present at the H.C. Wainwright Global Investment Conference

Trevena Reports First Quarter 2022 Results and Provides Business Update

Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects

Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund

OLINVYK® data selected as President’s Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting

Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group

Trevena Reports Fourth Quarter and Full Year 2021 Results

Trevena to Release Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022

Trevena to Participate in the Upcoming January Conferences

January 3, 2022

Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain

December 13, 2021

Trevena Reports Third Quarter 2021 Results

November 15, 2021

Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team

November 11, 2021

Trevena to Release Third Quarter 2021 Financial Results on November 15th, 2021

November 8, 2021

Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients

September 30, 2021

Trevena to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & MedTech Summit

September 17, 2021

Imvax Appoints John M. Limongelli as Chief Legal Officer

September 16, 2021

Trevena to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 9, 2021

Trevena Announces Two OLINVYK® Abstracts Highlighting Safety Data Accepted at ANESTHESIOLOGY® 2021

August 30, 2021

Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study

August 25, 2021

Trevena Reports Second Quarter 2021 Results

August 12, 2021

Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy

August 10, 2021

Trevena to Release Second Quarter 2021 Financial Results on August 12th, 2021

Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19

Trevena Announces Two Leading Independent Proxy Advisory Firms Recommend Shareholders Vote “For” All Proposals Ahead of Special Meeting of Stockholders

Profile

Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania.